Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.19% | 25.07% | 31.05% | 63.84% | 73.22% |
| Total Depreciation and Amortization | -38.31% | -45.51% | -49.51% | -38.72% | -28.34% |
| Total Amortization of Deferred Charges | 19.79% | 19.79% | 19.79% | 17.43% | 14.63% |
| Total Other Non-Cash Items | -98.73% | 80.75% | 87.69% | -98.19% | -97.38% |
| Change in Net Operating Assets | 96.76% | 97.11% | 97.27% | 74.34% | 47.48% |
| Cash from Operations | 36.51% | 53.13% | 62.62% | 55.53% | 49.71% |
| Capital Expenditure | -- | -- | -- | 52.98% | -75.94% |
| Sale of Property, Plant, and Equipment | -42.35% | -97.82% | -98.88% | -98.45% | -98.02% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 23.95% | -238.20% | -4,100.00% | -395.40% |
| Cash from Investing | 102.21% | 66.90% | -125.38% | -110.94% | -110.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -15.44% | -15.30% | -15.17% | 52.58% | 72.47% |
| Issuance of Common Stock | -- | -- | -- | 0.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -63.61% | 73.91% | 31,400.00% | 32.78% | -44.14% |
| Cash from Financing | -94.23% | -82.63% | -68.15% | 13.96% | 246.79% |
| Foreign Exchange rate Adjustments | -- | -660.00% | -330.00% | -135.48% | -100.00% |
| Miscellaneous Cash Flow Adjustments | 100.00% | 120.00% | -- | -- | -- |
| Net Change in Cash | -536.51% | -92.46% | 48.34% | 89.17% | 113.52% |